

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-072023-000202

Date: 27/7/23

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

CAPOX (Capecitabine with Oxaliplatin) - 1
FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) - 3
Lonsurf (Trifluridine - tipiracil) - 1
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 1
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) – 1
Any other systemic anti-cancer therapy - 9
Palliative care only - cannot specify

Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

Nivolumab monotherapy or combination with Ipilimumab - 3
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 1
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 5
Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) - 8
Any other systemic anti-cancer therapy – 6
Palliative care only - cannot specify

Q3. How many patients were treated in the past 3 months for advanced/metastatic resected oesophageal cancer ONLY with:

Nivolumab monotherapy or combination with Ipilimumab - 2
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 1
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 5

Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) - 7
Any other systemic anti-cancer therapy - 5
Palliative care only - cannot specify

Q4. In the past 3 months, how many patients have been initiated* on the following agents for treatment for gastric, gastro-oesophageal junction or Oesophageal cancer:

Nivolumab monotherapy or in combination with Ipilimumab – 2
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) – 1
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 7
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q5. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part. – see table below

Q6. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part. - see table below

IRAS Number	DGH disease area	Project Short title	Project Full title	Project site status	Recruited (total)
29926	Cancer	RTL Peri-operative Study	An analysis of Relative Telomere Length (RTL) during peri-operative chemotherapy in patients with operable gastric or gastro-oesophageal junction adenocarcinoma	Closed to recruitment - in follow up	16
120104	Oncology	Add-Aspirin	A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. <i>(includes gastro-oesophageal cancer)</i>	Open	56
315664	Palliative Care	QLG PATSAT 4	An international field study for the reliability and validity of the EORTC PATSAT-C33 core questionnaire and the EORTC OUT-PATSAT7 module <i>(includes gastro-oesophageal cancer)</i>	Open	6

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell’s Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

FOI/REF FOI-

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust